AKTS
Aktis Oncology, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Largest filed tie
0
filed ties
Fund move
Fund move
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
No thesis.
| Rank | Manager | Value | % 13F | ||
|---|---|---|---|---|---|
| 1 | MPM Oncology Impact ManagementMPM Oncology Impact | $155.9M | 14.15% | 0.00% | |
| 2 | EcoR1 CapitalEcoR1 Capital | $155.5M | 14.12% | 0.00% | |
| 3 | Blue Owl Capital HoldingsBlue Owl Capital | $99.0M | 8.99% | −2.88% | |
| 4 | BlackRockBlackRockindex-like | $73.4M | 6.67% | +7.87% | |
| 5 | T. Rowe Price Investment ManagementT. Rowe Price | $66.1M | 6.00% | −3.41% | |
| 6 | Wellington Management GroupWellington | $63.4M | 5.75% | −15.14% | |
| 7 | RTW InvestmentsRTW | $51.3M | 4.66% | 0.00% | |
| 8 | RA Capital ManagementRA Capital Management | $42.4M | 3.85% | −12.55% | |
| 9 | Jupiter TopcoJupiter Topco | $42.4M | 3.85% | — | |
| 10 | Baker Bros. AdvisorsBaker Bros. | $32.1M | 2.92% | 0.00% | |
| 11 | Octagon Capital AdvisorsOctagon Capital | $31.0M | 2.81% | 0.00% | |
| 12 | MerckMerck | $30.7M | 2.79% | 0.00% | |
| 13 | Vanguard Capital ManagementVanguardindex-like | $26.3M | 2.39% | −2.02% | |
| 14 | T. Rowe Price AssociatesT. Rowe Price | $24.6M | 2.23% | −51.19% | |
| 15 | TCG Crossover ManagementTCG Crossover | $22.5M | 2.04% | new | |
| 16 | Geode Capital ManagementGeodeindex-like | $16.8M | 1.52% | +5.85% | |
| 17 | Eventide Asset ManagementEventide | $16.3M | 1.48% | 0.00% | |
| 18 | Avidity Partners ManagementAvidity Partners | $15.6M | 1.42% | +3.34% | |
| 19 | State StreetState Streetindex-like | $15.6M | 1.42% | +13.02% | |
| 20 | AH Capital ManagementAH Capital Management | $13.4M | 1.21% | 0.00% | |
| 21 | Alyeska Investment GroupAlyeska Investment | $9.3M | 0.85% | 0.00% | |
| 22 | FMRFMR | $9.2M | 0.84% | −26.07% | |
| 23 | Arrowpoint Asset ManagementArrowpoint | $7.9M | 0.72% | −25.37% | |
| 24 | Northern TrustNorthern Trustindex-like | $5.8M | 0.53% | +20.81% | |
| 25 | Charles Schwab Investment ManagementCharles Schwabindex-like | $5.4M | 0.49% | +2.98% |
113 managers report $1.1B of Aktis Oncology on form 13F for the quarter ended Jun 30 '26. 14 of them hold 80% of it; MPM Oncology Impact is largest at 14.15%.
Aktis Oncology, Inc.
15.96
−0.89 · −5.31%
post 15.96 +0.02%
No implied move.
No implied move.
Expected move
No implied move.